You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,722,735

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,722,735 protect, and when does it expire?

Patent 8,722,735 protects IZBA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-two countries.

Summary for Patent: 8,722,735
Title:Pharmaceutical compositions having desirable bioavailability
Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
Inventor(s): Kabra; Bhagwati P. (Euless, TX), Carreras; Nuria (Barcelona, ES), Cuchi; Monica (Barcelona, ES), Galan; Francisco Javier (Teia, ES), Mridvika; (Barcelona, ES), Puig; Elena Gonzalez (Barcelona, ES), Jimenez; Nuria (Barcelona, ES), Martinez; Carmen (Barcelona, ES)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:13/252,255
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,722,735
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 8,722,735

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis IZBA travoprost SOLUTION/DROPS;OPHTHALMIC 204822-001 May 15, 2014 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,722,735

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 070888   Start Trial
Australia 2009225824   Start Trial
Canada 2716994   Start Trial
Chile 2009000624   Start Trial
China 101977588   Start Trial
China 105012964   Start Trial
Germany 202009019087   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.